Management of Gliclazide in Patients with Chronic Kidney Disease

Introduction to Gliclazide in CKD

The American Diabetes Association recommends gliclazide as one of the preferred second-generation sulfonylureas for patients with chronic kidney disease (CKD) who refuse insulin, due to its safety profile and lack of active metabolites that accumulate in kidney disease 1, 2, 3

For patients with CKD stage 4, start with a lower initial dose of gliclazide and titrate cautiously, monitoring blood glucose levels closely after initiation and with any dose adjustments 2
For patients with CKD stage 5 or end-stage renal failure, start with 30mg daily and titrate cautiously based on blood glucose response, considering less stringent glycemic targets (HbA1c ~7-8%) to minimize hypoglycemia risk 3
Implement more frequent blood glucose monitoring or continuous glucose monitoring (CGM) in patients with advanced CKD, as HbA1c becomes less reliable due to anemia and shortened red cell lifespan 1, 3

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines prioritize medications that do not increase hypoglycemia risk in advanced CKD, such as GLP-1 receptor agonists (e.g., dulaglutide, liraglutide, semaglutide) which have been studied with eGFR as low as 15 ml/min/1.73m² 4, 5
DPP-4 inhibitors like linagliptin require no dose adjustment in end-stage renal failure, and repaglinide can be started at 0.5mg with meals if eGFR <30 mL/min/1.73m² 2, 3

Never use first-generation sulfonylureas in any degree of renal impairment, and avoid glyburide entirely in CKD as it is contraindicated 1, 3
Avoid combining gliclazide with gemfibrozil as it increases hypoglycemia risk, and temporarily reduce or suspend gliclazide during acute illness, surgery, or prolonged fasting 1, 2